他克莫司治疗激素依赖性重症肌无力的临床疗效及安全性研究
详细信息 查看官网全文
- 英文论文题名：Clinical Efficacy and Safety of Tacrolimus in the Treatment of Hormone-Dependent Myasthenia Gravis
- 论文作者：顾文菊
- 英文论文作者：Gu Wenju
- 年：2017
- 作者机构：湖北省黄石市五医院;
- 论文关键词：疗效 ; 依赖性 ; 他克莫司 ; 重症肌无力 ; 疗效 ; 安全性
- 英文论文关键词：Efficacy ; Dependence ; Tacrolimus ; Myasthenia gravis ; Efficacy ; Safety
- 会议召开时间：2017-05-26
- 会议录名称：2017年《中国组织化学与细胞化学杂志》临床研讨会论文集
- 语种：中文
- 分类号：R746.1
- 学会代码：ZHXB
- 会议名称：2017年《中国组织化学与细胞化学杂志》临床研讨会
- 会议地点：中国湖北武汉
- 主办单位：《中国组织化学与细胞化学杂志》社有限公司
- 学会名称：《中国组织化学与细胞化学杂志》社有限公司
- 页数：2
- 文件大小：317k
- 原文格式：O
- 会议级别：全国
摘要
目的:分析研讨他克莫司治疗激素依赖性重症肌无力的临床疗效及安全性。方法:此研究为前瞻性研究,采用随机抽签方式从我院2015年2月至2016年3月期间收治的激素依赖性重症肌无力患者中,抽取126例纳入到讨论中,126例患者按入院单双顺序号分63例对照组(硫唑嘌呤治疗)和63例研究组(他克莫司药物治疗),对比研讨两组治疗状况。结果:对比两组患者治疗前MG疾病严重程度评分状况,组间数据无统计学意义(P>0.05);对比两组患者治疗后1周时、3周时、6周时、12周时MG疾病评分状况,研究组比对照组优,组间数据有统计学意义(P<0.05)。研究组总疗效92.06%比对照组的80.95%高,组间数据有统计学意义(P<0.05)。研究组总不良反应3.17%比对照组的9.52%低,组间数据有统计学意义(P<0.05)。结论:临床在治疗激素依赖性重症肌无力疾病时,可考虑给予他克莫司药物,其疗效和硫唑嘌呤进行对比,明显具有优势性,且可降低激素依赖性。
Objective:To investigate the clinical efficacy and safety of tacrolimus in the treatment of hormone-dependent myasthenia gravis.Methods:This prospective study was randomized to 126 patients with hormone-dependent myasthenia gravis admitted to our hospital from February 2015 to March 2016.126 patients were enrolled in the study 63 patients in the control group(azathioprine treatment) and 63 patients in the study group(tacrolimus drug treatment) were compared with those in the control group.Results:Compared with the two groups before treatment,the severity of MG disease score,the data between groups was not statistically significant(P > 0.05):Comparison of two groups of patients after treatment 1 week,3 weeks,6 weeks,12 weeks MG.The score of the disease was significantly higher in the study group than in the control group(P <0.05).The total efficacy of the study group was 92.06%higher than that of the control group(80.95%),and the data between the two groups was statistically significant(P <0.05).The total adverse events were 3.17%lower than the 9.52%in the control group,and the data were statistically significant(P < 0.05).Conclusion:In the treatment of hormone-dependent myasthenia gravis disease,tacrolimus drugs should be considered.The efficacy of azathioprine is superior to that of azathioprine,and it can decrease the hormone dependence.
Objective:To investigate the clinical efficacy and safety of tacrolimus in the treatment of hormone-dependent myasthenia gravis.Methods:This prospective study was randomized to 126 patients with hormone-dependent myasthenia gravis admitted to our hospital from February 2015 to March 2016.126 patients were enrolled in the study 63 patients in the control group(azathioprine treatment) and 63 patients in the study group(tacrolimus drug treatment) were compared with those in the control group.Results:Compared with the two groups before treatment,the severity of MG disease score,the data between groups was not statistically significant(P > 0.05):Comparison of two groups of patients after treatment 1 week,3 weeks,6 weeks,12 weeks MG.The score of the disease was significantly higher in the study group than in the control group(P <0.05).The total efficacy of the study group was 92.06%higher than that of the control group(80.95%),and the data between the two groups was statistically significant(P <0.05).The total adverse events were 3.17%lower than the 9.52%in the control group,and the data were statistically significant(P < 0.05).Conclusion:In the treatment of hormone-dependent myasthenia gravis disease,tacrolimus drugs should be considered.The efficacy of azathioprine is superior to that of azathioprine,and it can decrease the hormone dependence.
引文
[1]博求真,王磊,童卫杭等.CYP3A5基因多态性指导他克莫司治疗重症肌无力的初步探讨[J].中国神经免疫学和神经病学杂志,2013,20(1):17-19,23.
[2]王嘉佳,晏宁,唐玲等.小剂量他克莫司对糖皮质激素依赖性重症肌无力患者影响的meta分析[J].今日健康,2016,15(3):4-5.
[3]张文帅.他克莫司治疗难治性重症肌无力的疗效与安全性观察[J].临床医药文献电子杂志,2016,3(8):1569,1571.
[4]陈忠,李霞,李明娥等.82例他克莫司治疗难治性重症肌无力的可行性分析[J].中国伤残医学,2015,23(13):100-101.
[5]姚广明,赵真真.他克莫司治疗重症肌无力患者的临床效果及安全性评价[J].中国药物经济学,2016,11(11):55-57.
[2]王嘉佳,晏宁,唐玲等.小剂量他克莫司对糖皮质激素依赖性重症肌无力患者影响的meta分析[J].今日健康,2016,15(3):4-5.
[3]张文帅.他克莫司治疗难治性重症肌无力的疗效与安全性观察[J].临床医药文献电子杂志,2016,3(8):1569,1571.
[4]陈忠,李霞,李明娥等.82例他克莫司治疗难治性重症肌无力的可行性分析[J].中国伤残医学,2015,23(13):100-101.
[5]姚广明,赵真真.他克莫司治疗重症肌无力患者的临床效果及安全性评价[J].中国药物经济学,2016,11(11):55-57.